Ligand Pharmaceuticals (LGND) Non Operating Investment Income (2017 - 2026)

Ligand Pharmaceuticals has reported Non Operating Investment Income for 10 years, with the latest figure at $3.9 million in Q1 2026.

• Quarterly Non Operating Investment Income rose 131.28% year-over-year to $3.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $34.7 million (up 172.05% YoY) and the FY2025 annual result came in at $18.4 million, down 75.43% from the prior year.
• Non Operating Investment Income retreated to $3.9 million in Q1 2026 per LGND's latest filing, from $22.1 million in the prior quarter.
• Over five years, Non Operating Investment Income peaked at $110.8 million in Q1 2024 and troughed at -$23.9 million in Q4 2024.
• A 5-year average of $10.1 million and a median of $2.4 million in 2024 frame the typical range for Non Operating Investment Income.
• The sharpest annual moves came in 2022 and 2023: Non Operating Investment Income soared 430.27% in 2022, then plunged 1328.39% in 2023.
• Over 5 years, Non Operating Investment Income stood at $44.2 million in 2022, then slumped by 63.78% to $16.0 million in 2023, then slumped by 249.14% to -$23.9 million in 2024, then jumped by 192.32% to $22.1 million in 2025, then plunged by 82.46% to $3.9 million in 2026.
• According to Business Quant data, Non Operating Investment Income over the past three periods registered $3.9 million, $22.1 million, and $7.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.